Fortis Life Sciences Acquires Abcore, a Leader in Single-Domain Antibody Technologies
March 2, 2022
Extends company capabilities into VHH and antibody discovery and development.
WALTHAM, MA – Fortis Life Sciences has acquired Abcore, a San Diego, California, USA based antibody discovery platform specializing in single-domain antibody technology. With the addition of Abcore, Fortis extends its capabilities into the antibody discovery market serving biopharma customers developing antibody and VHH-based therapeutics.
Brian Kim, Chief Executive Officer of Fortis, remarked on the partnership, “Abcore is a powerful addition to the Fortis portfolio and deepens our antibody product and service capabilities. We are particularly optimistic about the potential of single-domain antibody technologies in therapeutic and diagnostic applications. Our acquisition of Abcore aligns perfectly with Fortis’ goal of partnering with and investing in world-class life sciences companies seeking a strategic growth partner.”
“We are excited about accelerating Abcore’s growth as part of the Fortis family,” added David Barraclough, Chief Executive Officer of Abcore. “Fortis shares our commitment to scientific discovery, innovation, and customer service and is the ideal partner for Abcore as we expand our technical capabilities and bring new products and services to market.” Jennifer Johnson, President of Abcore, also added, “Our partnership with Fortis will provide Abcore with the commercial and operational infrastructure necessary for us to focus on developing high-quality products and better serving our customers.”
Pivotal Scientific Ltd. acted as the exclusive corporate advisor to Abcore.
Abcore, based in San Diego, CA, provides antibody and VHH products and services. Abcore has built an entire platform for single-domain antibody (VHH) discovery, based on proprietary phage display libraries. The Company offers end-to-end discovery and development capabilities and custom antibody production. View more at www.abcore.com
Fortis partners with diagnostics and life sciences companies to custom-design, validate, and manufacture proprietary solutions to solve their most difficult development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across the world including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities in North America. To learn more about Fortis, please visit www.fortislife.com.
